OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review)
Ling Yang, Hongjian Xie, Yingying Li, et al.
Oncology Reports (2022) Vol. 47, Iss. 4
Open Access | Times Cited: 139
Ling Yang, Hongjian Xie, Yingying Li, et al.
Oncology Reports (2022) Vol. 47, Iss. 4
Open Access | Times Cited: 139
Showing 1-25 of 139 citing articles:
Role of NRF2 in Ovarian Cancer
Giovanni Tossetta, Sonia Fantone, Eva Montanari, et al.
Antioxidants (2022) Vol. 11, Iss. 4, pp. 663-663
Open Access | Times Cited: 81
Giovanni Tossetta, Sonia Fantone, Eva Montanari, et al.
Antioxidants (2022) Vol. 11, Iss. 4, pp. 663-663
Open Access | Times Cited: 81
Targeting the NRF2/KEAP1 pathway in cervical and endometrial cancers
Giovanni Tossetta, Daniela Marzioni
European Journal of Pharmacology (2023) Vol. 941, pp. 175503-175503
Closed Access | Times Cited: 61
Giovanni Tossetta, Daniela Marzioni
European Journal of Pharmacology (2023) Vol. 941, pp. 175503-175503
Closed Access | Times Cited: 61
Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance
Ebrahim H. Maleki, Ahmad Reza Bahrami, Maryam Moghaddam Matin
Genes & Diseases (2023) Vol. 11, Iss. 1, pp. 189-204
Open Access | Times Cited: 53
Ebrahim H. Maleki, Ahmad Reza Bahrami, Maryam Moghaddam Matin
Genes & Diseases (2023) Vol. 11, Iss. 1, pp. 189-204
Open Access | Times Cited: 53
ALDH and cancer stem cells: Pathways, challenges, and future directions in targeted therapy
Kousalya Lavudi, Shreya Madhav Nuguri, Prashant Pandey, et al.
Life Sciences (2024) Vol. 356, pp. 123033-123033
Closed Access | Times Cited: 13
Kousalya Lavudi, Shreya Madhav Nuguri, Prashant Pandey, et al.
Life Sciences (2024) Vol. 356, pp. 123033-123033
Closed Access | Times Cited: 13
Optimizing Therapeutics for Intratumoral Cancer Treatments: Antiproliferative Vanadium Complexes in Glioblastoma
Angie Bates, Kameron L. Klugh, Anna O. Galaeva, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 994-994
Open Access | Times Cited: 1
Angie Bates, Kameron L. Klugh, Anna O. Galaeva, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 994-994
Open Access | Times Cited: 1
Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings
Giovanni Tossetta
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 12893-12893
Open Access | Times Cited: 51
Giovanni Tossetta
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 12893-12893
Open Access | Times Cited: 51
Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways
Mohammad Yasin Zamanian, Maryam Golmohammadi, Alexey Yumashev, et al.
Cell Biochemistry and Function (2024) Vol. 42, Iss. 4
Open Access | Times Cited: 7
Mohammad Yasin Zamanian, Maryam Golmohammadi, Alexey Yumashev, et al.
Cell Biochemistry and Function (2024) Vol. 42, Iss. 4
Open Access | Times Cited: 7
Snail transcription factors as key regulators of chemoresistance, stemness and metastasis of ovarian cancer cells
Michał Kiełbik, Patrycja Przygodzka, Izabela Szulc-Kiełbik, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 189003-189003
Open Access | Times Cited: 19
Michał Kiełbik, Patrycja Przygodzka, Izabela Szulc-Kiełbik, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 189003-189003
Open Access | Times Cited: 19
Enzymatically crosslinked magnetic starch-grafted poly(tannic acid) hydrogel for “smart” cancer treatment: An in vitro chemo/hyperthermia therapy study
Morteza Eskandani, Hossein Derakhshankhah, Soheila Zare, et al.
International Journal of Biological Macromolecules (2023) Vol. 253, pp. 127214-127214
Closed Access | Times Cited: 18
Morteza Eskandani, Hossein Derakhshankhah, Soheila Zare, et al.
International Journal of Biological Macromolecules (2023) Vol. 253, pp. 127214-127214
Closed Access | Times Cited: 18
Therapeutic strategies targeting folate receptor α for ovarian cancer
Jia Mai, Limei Wu, Ling Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Jia Mai, Limei Wu, Ling Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Combined radiomics-clinical model to predict platinum-sensitivity in advanced high-grade serous ovarian carcinoma using multimodal MRI
Inye Na, Joseph J. Noh, Chan Kyo Kim, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Inye Na, Joseph J. Noh, Chan Kyo Kim, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review
Effat Alemzadeh, Leila Allahqoli, Afrooz Mazidimoradi, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 831-847
Open Access | Times Cited: 5
Effat Alemzadeh, Leila Allahqoli, Afrooz Mazidimoradi, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 831-847
Open Access | Times Cited: 5
Emerging role of m6A modification in ovarian cancer: progression, drug resistance, and therapeutic prospects
Shahil Alam, P. Giri
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Shahil Alam, P. Giri
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Lactate drives the ESM1–SCD1 axis to inhibit the antitumor CD8+ T-cell response by activating the Wnt/β-catenin pathway in ovarian cancer cells and inducing cisplatin resistance
Zhiwen Fan, Mingzhu Ye, Dan Liu, et al.
International Immunopharmacology (2024) Vol. 137, pp. 112461-112461
Closed Access | Times Cited: 5
Zhiwen Fan, Mingzhu Ye, Dan Liu, et al.
International Immunopharmacology (2024) Vol. 137, pp. 112461-112461
Closed Access | Times Cited: 5
Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer
Trudy Janice Philips, Britt Erickson, Stefani N. Thomas
Frontiers in Oncology (2025) Vol. 14
Open Access
Trudy Janice Philips, Britt Erickson, Stefani N. Thomas
Frontiers in Oncology (2025) Vol. 14
Open Access
LncRNA MIR17HG drives cisplatin resistance partially via miR-138-5p/AKAP9 axis in cholangiocarcinoma
Ling‐Yu Tang, Yuting Wang, Yongzhen Chen, et al.
Scandinavian Journal of Gastroenterology (2025), pp. 1-13
Closed Access
Ling‐Yu Tang, Yuting Wang, Yongzhen Chen, et al.
Scandinavian Journal of Gastroenterology (2025), pp. 1-13
Closed Access
CT-based radiomics predicts HRD score and HRD status in patients with ovarian cancer
Yujiao Wu, Qianhui Zhang, Wenyan Jiang, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Yujiao Wu, Qianhui Zhang, Wenyan Jiang, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Self-assembled HO-1i-Pt(IV) nanomedicine targeting p38/MAPK and MDR pathways for cancer chemo-immunotherapy
Xiaomeng Liu, Zhe Li, Xiaoya Wang, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 797-813
Closed Access
Xiaomeng Liu, Zhe Li, Xiaoya Wang, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 797-813
Closed Access
Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications
Sneha Basu, Revathy Nadhan, Danny N. Dhanasekaran
Cancers (2025) Vol. 17, Iss. 3, pp. 472-472
Open Access
Sneha Basu, Revathy Nadhan, Danny N. Dhanasekaran
Cancers (2025) Vol. 17, Iss. 3, pp. 472-472
Open Access
Emerging Therapeutic Targets for Platinum-Resistant Ovarian Cancer
Connor Wang, Maria Gomez-Roas, Emily Hinchcliff
Advances in Oncology (2025)
Closed Access
Connor Wang, Maria Gomez-Roas, Emily Hinchcliff
Advances in Oncology (2025)
Closed Access
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
Amit M. Oza, Alla Lisyanskaya, Alexander N. Fedenko, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 2, pp. 249-264
Closed Access
Amit M. Oza, Alla Lisyanskaya, Alexander N. Fedenko, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 2, pp. 249-264
Closed Access
Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
Hao Su, Xiao Shang, Hongruo Liu, et al.
International Journal of Women s Health (2025) Vol. Volume 17, pp. 325-333
Open Access
Hao Su, Xiao Shang, Hongruo Liu, et al.
International Journal of Women s Health (2025) Vol. Volume 17, pp. 325-333
Open Access
Clinical Impact of Olaparib for Platinum-Sensitive Recurrent Ovarian Cancer
Hiroaki Ishida, Megumi Manrai, Akiko Takashima, et al.
Diseases (2025) Vol. 13, Iss. 2, pp. 51-51
Open Access
Hiroaki Ishida, Megumi Manrai, Akiko Takashima, et al.
Diseases (2025) Vol. 13, Iss. 2, pp. 51-51
Open Access
Host Defense Peptide Mimics Synergize with Pt(IV) Prodrugs for Surmounting Cisplatin Resistance via Selective Cancer Membrane Disruption
Anqi Shen, Xiangyong He, Shuo Tang, et al.
ACS Applied Materials & Interfaces (2025)
Closed Access
Anqi Shen, Xiangyong He, Shuo Tang, et al.
ACS Applied Materials & Interfaces (2025)
Closed Access
Urinary concentrations of phthalate metabolites and the survival of high-grade serous ovarian cancer with advanced stage
Wenrui Zheng, Yi-Zi Li, Jun Xu, et al.
Environmental Pollution (2025), pp. 125895-125895
Closed Access
Wenrui Zheng, Yi-Zi Li, Jun Xu, et al.
Environmental Pollution (2025), pp. 125895-125895
Closed Access
